The Combined Effect of black cohosh, soybean, arctium lappa L and vitex agnus- castus extracts On menopause
Not Applicable
- Conditions
- menopause.Menopausal and other perimenopausal disorders
- Registration Number
- IRCT20170430033730N8
- Lead Sponsor
- Qazvin University of Medical Sciences
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete
- Sex
- Female
- Target Recruitment
- 54
Inclusion Criteria
Having menopausal symptoms
Exclusion Criteria
patients who do not want to cooperate
People who smoke
People who drink alcohol
Patients with gastrointestinal disorders
Diabetic Patients
Thyroid disease, breast and ovarian cancer, liver and neurological disorders, high blood pressure, taking anticoagulants
Study & Design
- Study Type
- interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Clinical symptoms. Timepoint: Beginning and end of the study. Method of measurement: Quality of life questionnaire for menopausal women.
- Secondary Outcome Measures
Name Time Method Glutathione. Timepoint: Beginning and end of the study. Method of measurement: Spectrophotometry.;MDA. Timepoint: Beginning and end of the study. Method of measurement: Spectrophotometry.;TNF-a. Timepoint: Beginning and end of the study. Method of measurement: ELISA.;IL-8. Timepoint: Beginning and end of the study. Method of measurement: ELISA.;Gonadotropins. Timepoint: Beginning and end of the study. Method of measurement: ELISA.;E2. Timepoint: Beginning and end of the study. Method of measurement: ELISA.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular pathways do black cohosh, soybean, arctium lappa L, and vitex agnus-castus extracts modulate in menopausal symptoms?
How does the IRCT20170430033730N8 herbal combination compare to hormone replacement therapy in managing oxidative stress biomarkers in menopausal women?
Which inflammatory and oxidative stress biomarkers predict response to the IRCT20170430033730N8 herbal formulation in menopausal patients?
What are the potential adverse events of combined black cohosh, soybean, arctium lappa L, and vitex agnus-castus extracts in menopausal women, and how are they managed?
Are there synergistic effects between phytoestrogens (e.g., isoflavones) and neurosteroid modulators in the IRCT20170430033730N8 trial for perimenopausal disorders?